Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.

about

Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis.

P2860

Q38430117-224AE28A-C87A-4330-BCB6-F8B521C6E5FF

P2860

Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.

Item

http://www.wikidata.org/entity/Q53786443

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Classical Hodgkin lymphoma pri ...... diffuse large B-cell lymphoma.

@en

Classical Hodgkin lymphoma pri ...... diffuse large B-cell lymphoma.

@nl

type

Item

label

Classical Hodgkin lymphoma pri ...... diffuse large B-cell lymphoma.

@en

Classical Hodgkin lymphoma pri ...... diffuse large B-cell lymphoma.

@nl

prefLabel

Classical Hodgkin lymphoma pri ...... diffuse large B-cell lymphoma.

@en

Classical Hodgkin lymphoma pri ...... diffuse large B-cell lymphoma.

@nl

P1476

Classical Hodgkin lymphoma pri ...... diffuse large B-cell lymphoma.

@en

P2093

Akiko Miyagi Maeshima

http://www.w3.org/2001/XMLSchema#string

Dai Maruyama

http://www.w3.org/2001/XMLSchema#string

Hideaki Kitahara

http://www.w3.org/2001/XMLSchema#string

Hirokazu Taniguchi

http://www.w3.org/2001/XMLSchema#string

Kensei Tobinai

http://www.w3.org/2001/XMLSchema#string

Suguru Fukuhara

http://www.w3.org/2001/XMLSchema#string

Tatsuya Suzuki

http://www.w3.org/2001/XMLSchema#string

Wataru Munakata

http://www.w3.org/2001/XMLSchema#string

P2860

Immunoglobulin gene rearrangement analysis in composite hodgkin disease and large B-cell lymphoma: evidence for receptor revision of immunoglobulin heavy chain variable region genes in Hodgkin-Reed-Sternberg cells?

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin.

Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma

Brentuximab vedotin in relapsed/refractory Hodgkin's lymphoma: the Italian experience and results of its use in daily clinical practice outside clinical trials

Persistence of CD30 expression in Hodgkin lymphoma following brentuximab vedotin (SGN-35) treatment failure

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project.

Microtubules and resistance to tubulin-binding agents.

Advances in the treatment of Hodgkin lymphoma.

Large B-cell lymphoma with Hodgkin's features.

P2888

s12185-016-2018-y

P304

396-399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12185-016-2018-Y

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

Yukio Kobayashi

Shinichi Makita

P577

2016-05-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27169615

http://www.w3.org/2001/XMLSchema#string

Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.

about

P2860

P2860

Classical Hodgkin lymphoma primary refractory to brentuximab vedotin, with transformation to CD30-positive diffuse large B-cell lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698